NexoBrid (anacaulase-bcdb) approved for the Treatment of Severe Thermal Burns in Adults
December 22, 2022Lunsumio approval from FDA for treatment of adults with relapsed or refractory follicular lymphoma
December 22, 2022December 22, 2022 - Gilead Sciences, Inc. has announced that Sunlenca ® (lenacapavir), in combination with other antiretroviral(s) (ARV), has been granted approval by the U.S. Food and Drug Administration (FDA) for the treatment of HIV-1 infection in heavily treatment-experienced (HTE) adults with multi-drug resistant (MDR) HIV-1 infection.
Sunlenca belongs to a new class of drugs called capsid inhibitors and is designed to inhibit HIV-1 at multiple stages of its lifecycle and may work against HIV strains that are resistant to other HIV drugs. Sunlenca offers a new, twice-yearly treatment option for adults with HIV that is not adequately controlled by their current treatment regimen.